News archive.
Earlier AI news and analysis, kept for reference. Current coverage lives in News & Analysis.
Indian study links vitamin D, B12 deficiency to higher dementia risk
ICMR-NIN research of 570 adults found 40% had elevated dementia risk scores, with vitamin D, B2, B6, and B12 deficiencies far more common in the higher-risk group. The findings point to nutrition as a modifiable prevention target.
76% of clinical trials need protocol rewrites—AI can predict them upfront
Static trial protocols drive costly amendments months into execution. Machine learning trained on real trial data can now flag design flaws before enrollment starts, cutting delays and site burden.
J&J buys Firefly for $1B to merge protein degraders with antibody drugs
Johnson & Johnson is acquiring Firefly Biotech for $1 billion to gain access to a hybrid drug platform combining protein degraders and antibody-drug conjugates. Here's what the combo technology does.
Incyte to buy Vega for $2B blood disorder drug in late-stage trials
Incyte is acquiring Vega Therapeutics, a spinoff from Star Biotech, for roughly $2B to add a bleeding-control medicine in late-stage development. What the deal signals about pharma M&A in biotech.
Tango's pancreatic cancer combo lifts response rates in early trial
Tango Therapeutics' experimental drug combination showed response rates well above historical expectations in a small clinical trial, sending shares higher. Early data raises questions about potential efficacy in a field with limited treatment options.
Roche bets $700M that protein-degrading drugs beat enzyme blockers
Roche is investing $700 million upfront in Nurix's BTK protein degrader, with potential total value reaching $2.3 billion. The bet hinges on whether destroying the enzyme outperforms existing drugs that merely inhibit it.
City Therapeutics raises $100M for RNA drugs backed by Alnylam founder
City Therapeutics, co-founded by former Alnylam CEO John Maraganore, secured nearly $100M in Series B funding. The biotech is advancing an RNAi drug for a blood clotting disorder into human trials, with a Stargardt disease candidate in the pipeline.
Boston Scientific builds Indiana hub for global device distribution
Boston Scientific is constructing a distribution center in Indiana near a principal manufacturing facility to handle global shipments of its medical devices. The move consolidates logistics operations.
Three diabetes device makers present data at ADA conference
Tandem Diabetes Care, Insulet, and Dexcom showed new findings at the American Diabetes Association's Scientific Sessions. What each company revealed and why it matters for patients.
Half of Medicaid enrollees don't know work rules start in 6 months
A Health Management Academy survey found over 50% of Medicaid recipients are unaware of upcoming work, education, or volunteer hour reporting requirements. Enrollment deadline approaches with no clear communication plan.
Cities sue to block ACA rule that's raising uninsured rates
City leaders filed suit to overturn a federal regulation they say undermines Affordable Care Act exchanges and shifts costs to local governments. Here's what triggered the lawsuit.
Central Labs Now Define Clinical Trial Success—Here's What Sponsors Miss
Central laboratories have become critical infrastructure for clinical trials as complexity rises. Sponsors choosing the wrong lab partner face delays, cost overruns, and regulatory friction—here's how to evaluate them.